Yamamoto T - Search Results

1

Ptf1a and RBP-J cooperate in activating Pdx1 gene expression through binding to Area III.

Miyatsuka T, Matsuoka TA, Shiraiwa T, Yamamoto T, Kojima I, Kaneto H. Miyatsuka T, et al. Among authors: yamamoto t. Biochem Biophys Res Commun. 2007 Nov 3;362(4):905-9. doi: 10.1016/j.bbrc.2007.08.076. Epub 2007 Aug 24. Biochem Biophys Res Commun. 2007. PMID: 17803961

2

Regulation of MafA expression in pancreatic beta-cells in db/db mice with diabetes.

Matsuoka TA, Kaneto H, Miyatsuka T, Yamamoto T, Yamamoto K, Kato K, Shimomura I, Stein R, Matsuhisa M. Matsuoka TA, et al. Among authors: yamamoto k, yamamoto t. Diabetes. 2010 Jul;59(7):1709-20. doi: 10.2337/db08-0693. Epub 2010 Apr 27. Diabetes. 2010. PMID: 20424231 Free PMC article.

3

Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.

Kawashima S, Matsuoka TA, Kaneto H, Tochino Y, Kato K, Yamamoto K, Yamamoto T, Matsuhisa M, Shimomura I. Kawashima S, et al. Among authors: yamamoto k, yamamoto t. Biochem Biophys Res Commun. 2011 Jan 7;404(1):534-40. doi: 10.1016/j.bbrc.2010.12.021. Epub 2010 Dec 7. Biochem Biophys Res Commun. 2011. PMID: 21144823

4

Basal insulin requirement is ~30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump.

Kuroda A, Kaneto H, Yasuda T, Matsuhisa M, Miyashita K, Fujiki N, Fujisawa K, Yamamoto T, Takahara M, Sakamoto F, Matsuoka TA, Shimomura I. Kuroda A, et al. Among authors: yamamoto t. Diabetes Care. 2011 May;34(5):1089-90. doi: 10.2337/dc10-2149. Epub 2011 Mar 23. Diabetes Care. 2011. PMID: 21430086 Free PMC article.

5

Subclinical hypothyroidism is independently associated with albuminuria in people with type 2 diabetes.

Yasuda T, Kaneto H, Kuroda A, Yamamoto T, Takahara M, Naka T, Miyashita K, Fujisawa K, Sakamoto F, Katakami N, Matsuoka TA, Shimomura I. Yasuda T, et al. Among authors: yamamoto t. Diabetes Res Clin Pract. 2011 Dec;94(3):e75-7. doi: 10.1016/j.diabres.2011.08.019. Epub 2011 Sep 16. Diabetes Res Clin Pract. 2011. PMID: 21925759

6

Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).

Katakami N, Mita T, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Watada H, Shimomura I; Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis Trial. Katakami N, et al. Among authors: yamamoto t. J Atheroscler Thromb. 2013;20(12):893-902. doi: 10.5551/jat.18333. Epub 2013 Aug 20. J Atheroscler Thromb. 2013. PMID: 23965491 Free article. Clinical Trial.

7

Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE).

Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, Yamamoto T, Matsumoto K, Yokoyama H, Tsugawa M, Gosho M, Shimomura I, Watada H. Mita T, et al. Among authors: yamamoto t. Diabetol Metab Syndr. 2014 Mar 10;6(1):35. doi: 10.1186/1758-5996-6-35. Diabetol Metab Syndr. 2014. PMID: 24607023 Free PMC article.

8

Clinical and endocrinological characteristics of adrenal incidentaloma in Osaka region, Japan.

Tabuchi Y, Otsuki M, Kasayama S, Kosugi K, Hashimoto K, Yamamoto T, Tsugawa M, Mineo I, Yamada Y, Kurebayashi S, Ohashi M, Umayahara Y, Kouhara H, Nakamura T, Taki H, Matsuoka TA, Imagawa A, Funahashi T, Shimomura I. Tabuchi Y, et al. Among authors: yamamoto t. Endocr J. 2016;63(1):29-35. doi: 10.1507/endocrj.EJ15-0404. Epub 2015 Oct 22. Endocr J. 2016. PMID: 26490049 Free article.

9

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).

Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Shimomura I, Watada H; Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial. Mita T, et al. Among authors: yamamoto t. Diabetes Care. 2016 Jan;39(1):139-48. doi: 10.2337/dc15-0781. Epub 2015 Dec 1. Diabetes Care. 2016. PMID: 26628419 Clinical Trial.

10

Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.

Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, Yamamoto T, Matsumoto K, Yokoyama H, Tsugawa M, Gosho M, Shimomura I, Watada H; Collaborators on the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE) Trial. Mita T, et al. Among authors: yamamoto t. Diabetes Care. 2016 Mar;39(3):455-64. doi: 10.2337/dc15-2145. Epub 2016 Jan 28. Diabetes Care. 2016. PMID: 26822324 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17,377 results

Search Page

Filters